Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study Meeting Abstract
| Authors: | Modi, S.; Jacot, W.; Iwata, H.; Park, Y. H.; Losada, M. J. V.; Li, W.; Tsurutani, J.; Zaman, K.; Ueno, N. T.; Prat, A.; Papazisis, K.; Rugo, H. S.; Harbeck, N.; Im, S. A.; De Laurentiis, M.; Orbegoso, C. M. A.; Yung, L.; Cheng, F. C.; Cheng, Y.; Cameron, D. A. |
| Abstract Title: | Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S334 |
| End Page: | S335 |
| Language: | English |
| ACCESSION: | WOS:001087480200365 |
| DOI: | 10.1016/j.annonc.2023.09.553 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 376O -- Source: Wos |
